Prognostic Implications of Immune-Related Gene Pairs Signatures in Bladder Cancer

Figure 2

Development of the prognostic signature based on IRGPs in the TCGA-training set. (a, b) Identification of 37 IRGPs by LASSO regression analysis; (c) distribution of risk scores based on IRGPs in bladder patients; (d) survival status of patients in different groups; (e) heatmap of the expression profiles of IRGPs; (f) survival analysis for the signature-defined risk groups; (g) time-dependent ROC curve of the 37-IRGPs prognostic signature.

(a)

(b)

(c)

(d)

(e)

(f)

(g)